Interesting Image

68Ga-FAPI-04 PET/CT Findings in Patients with Liver Cirrhosis


  • Gamze Tatar
  • Ediz Beyhan
  • Özge Erol Fenercioğlu
  • İsa Sevindi
  • Nurhan Ergül
  • Tevfik Fikret Çermik

Received Date: 06.08.2022 Accepted Date: 12.12.2022 Mol Imaging Radionucl Ther 2023;32(2):146-149 PMID: 37337827

Fibroblast activation protein (FAP) is expressed as a pro-inflammatory agent from fibrous tissue in liver cirrhosis and in the tumor microenvironment. Cirrhosis is the last stage of any chronic liver disease, and the natural course of cirrhosis is the progression from the asymptomatic phase to the symptomatic decompensated phase with the development of ascites. Although various clinical features suggest cirrhosis in patients with chronic liver disease, non-invasive methods should follow the clinical approach before a definitive diagnosis. Herein, we present three cases of liver cirrhosis with fibroblast activation protein inhibitor (FAPI) uptake to demonstrate the usefulness of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) scan in cirrhosis.

Keywords: PET/CT, 68Ga FAPI-04, cirrhosis, liver, molecular imaging


Informed Consent: Informed consent was obtained from the patients included in the study.

Peer-review: Externally and internally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: G.T., E.B., Ö.E.F., İ.S., N.E., T.F.Ç., Concept: G.T., E.B., Ö.E.F., İ.S., N.E., T.F.Ç., Design: G.T., E.B., Ö.E.F., İ.S., N.E., T.F.Ç., Data Collection or Processing: G.T., E.B., Ö.E.F., İ.S., N.E., T.F.Ç., Analysis or Interpretation: G.T., E.B., Ö.E.F., İ.S., N.E., T.F.Ç., Literature Search: G.T., E.B., Ö.E.F., İ.S., Writing: G.T., T.F.Ç.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.


  1. Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-1376.
  2. Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol 2014;20:7312-7324.
  3. Çermik TF, Ergül N, Yılmaz B, Mercanoğlu G. Tumor imaging with 68Ga-DOTA-FAPI-04 PET/CT: comparison with 18F-FDG PET/CT in 22 different cancer types 2022;47:333-339.
  4. Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, Wu X, Guo W, Fan C, Wu J, Huang W, Lin Q, Sun L, Wu H. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging 2021;48:73-86.
  5. Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S, Tripathi M, ArunRaj ST, Sarswat S, Bal C. Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers. Eur J Nucl Med Mol Imaging 2021;48:1915-1931.
  6. Shi X, Xing H, Yang X, Li F, Yao S, Congwei J, Zhao H, Hacker M, Huo L, Li X. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging 2021;48:1593-1603.
  7. Shi X, Xing H, Yang X, Li F, Yao S, Zhang H, Zhao H, Hacker M, Huo L, Li X. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol Imaging 2021;48:196-203.
  8. Zhao L, Gu J, Fu K, Lin Q, Chen H. 68Ga-FAPI PET/CT in assessment of liver nodules in a cirrhotic patient. Clin Nucl Med 2020;45:430-432.